Board member Allan Rosetzsky resigns

Report this content

Hørsholm, Denmark, October 6, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that Allan Rosetzsky, with immediate effect, has decided to resign from ExpreS2ion’s board of directors. Hereafter the board of directors will consist of Martin Roland Jensen (Chair), Jakob Knudsen, Karin Garre, and Sara Sande.

I have been an investor in ExpreS2ion since inception in 2010, and it is with great joy that I have participated in taking this unique company public in 2016 and been part of its growth journey in the recent 5-6 years. Time has come for me to resign, and I am glad that the remaining board of directors is in capable hands to take the pipeline-focused strategy forward,” comments Allan Rosetzsky.

I appreciate Allan’s contribution in ExpreS2ion’s board, and I wish Allan all the best in his continued role as business angel in other ventures. Now the rest of us in the board of directors will continue to support management in the execution of the pipeline-focused strategy that we embarked on in 2020. I believe that we have growth opportunities at hand that can grow the shareholder value in the foreseeable future,” comments Martin Roland Jensen, Chairman.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
+46 11 32 30 732


For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

Keith Alexander, CFO
Telephone: +45 5131 8147


About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply through the clinical development value chain from Phase I to Phase III. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. Since 2020, the Company is focusing on its development pipeline of high-value assets within infectious diseases and oncology. For additional information, please visit